How Growth Hormone Affects Fasting Insulin

Exogenous GH drives compensatory hyperinsulinemia through a well-characterised sequence of metabolic events:

1. The Randle cycle (fatty acid-glucose competition): GH is a potent lipolytic hormone that increases circulating free fatty acids (FFAs). Elevated FFAs compete with glucose for oxidation in skeletal muscle, a process called the Randle cycle. When muscle cells preferentially burn FFAs, they reduce glucose uptake, creating peripheral insulin resistance.
2. Impaired insulin signalling: GH directly interferes with insulin receptor substrate (IRS-1) phosphorylation in muscle and adipose tissue, reducing GLUT4 glucose transporter translocation to the cell surface. Less GLUT4 means less glucose entry into cells.
3. Hepatic glucose output: GH stimulates gluconeogenesis in the liver, adding more glucose to the bloodstream even in the fasted state.
4. Compensatory hyperinsulinemia: Faced with rising blood glucose, pancreatic beta cells increase insulin secretion to force glucose into resistant cells. Fasting insulin rises as the beta cells work harder to maintain glucose homeostasis.

The critical insight is that fasting insulin rises before fasting glucose. The pancreas successfully compensates for months or even years by producing more insulin, keeping glucose in the normal range. By the time fasting glucose finally rises, the beta cells are already under significant stress. This is why fasting insulin is the earliest and most sensitive metabolic marker for GH-induced insulin resistance.

The HOMA-IR formula (fasting insulin [mIU/L] x fasting glucose [mg/dL] / 405) quantifies this insulin-glucose relationship and serves as a practical tool for tracking insulin resistance progression.

Low-dose (1-3 IU/day):

• Fasting insulin: 5-12 mIU/L (may remain within normal range)
• HOMA-IR: typically under 1.5
• Minimal metabolic impact for most lean, active individuals

Moderate doses (4-6 IU/day):

• Fasting insulin: 10-20 mIU/L
• HOMA-IR: 1.5-2.5
• Detectable compensatory hyperinsulinemia; glucose may still appear normal
• Beta cells are working harder but managing

High doses (8-15+ IU/day):

• Fasting insulin: 15-30+ mIU/L
• HOMA-IR: above 2.5, often 3.0-5.0
• Frank insulin resistance; glucose may begin rising as beta-cell compensation fails
• Long-term beta-cell exhaustion risk becomes significant

HOMA-IR benchmarks for lean athletes:

• Below 1.0: optimal insulin sensitivity
• 1.0-1.5: normal range
• 1.5-2.0: mild insulin resistance, warrants dietary attention
• 2.0-2.5: moderate insulin resistance, intervention recommended
• Above 2.5: significant insulin resistance, dose reduction or medication needed

Timeline: Fasting insulin typically begins rising within 1-2 weeks of starting GH. HOMA-IR increases progressively over weeks to months. The insulin rise precedes any glucose elevation by weeks to months.

Baseline: Obtain fasting insulin and fasting glucose before starting GH. Calculate baseline HOMA-IR. Both tests must be truly fasted (10-12 hours, water only). Even a small amount of food can invalidate fasting insulin measurements.

During use:

• Fasting insulin + fasting glucose: every 3-6 months (always at the same fasting duration)
• Calculate HOMA-IR at each blood draw and track the trend over time
• HbA1c every 3 months as a complementary chronic marker
• Consider adding a 2-hour oral glucose tolerance test (OGTT) with insulin levels if HOMA-IR is trending upward but fasting glucose remains normal

Interpreting the insulin-glucose dissociation:

• Rising insulin + normal glucose = early insulin resistance (beta cells compensating successfully)
• Rising insulin + rising glucose = progressive insulin resistance (beta-cell compensation failing)
• High insulin + high glucose = established insulin resistance, possible beta-cell dysfunction

Practical tip: Always request the actual fasting insulin value from your lab, not just a "normal/abnormal" flag. Many labs consider fasting insulin up to 25 mIU/L as "normal," which is far too permissive for a lean, active athlete. For bodybuilders, aim for a fasting insulin below 8-10 mIU/L.

HOMA-IR is the actionable metric:

• Track HOMA-IR over time rather than individual insulin or glucose values
• A trending increase (even within "normal" ranges) is the signal to act
• Intervention thresholds: begin dietary changes at HOMA-IR above 1.5, add supplements at 2.0, consider metformin at 2.5

Dietary optimisation for insulin sensitivity:

• Reduce processed carbohydrates and refined sugars
• Increase soluble fibre (psyllium, oats, legumes) to 30-40 g/day
• Prioritise monounsaturated fats (olive oil, avocado, nuts) over saturated fats
• Time carbohydrate intake around training when GLUT4 translocation is insulin-independent

Exercise timing matters:

• Resistance training and high-intensity cardio improve insulin sensitivity for 24-48 hours post-session
• Scheduling GH injection before training may partially offset the insulin resistance through exercise-mediated glucose uptake
• Regular aerobic exercise (150+ minutes/week) is one of the most effective interventions for insulin sensitivity

Supplement support:

• Berberine 500 mg 2-3x daily with meals (activates AMPK, comparable to metformin in multiple trials)
• Alpha-lipoic acid 300-600 mg/day (improves insulin signalling)
• Chromium picolinate 200-1000 mcg/day (enhances insulin receptor sensitivity)

Pharmaceutical intervention:

• Metformin 500-1000 mg/day if HOMA-IR exceeds 2.0-2.5 despite lifestyle measures
• Metformin reduces hepatic glucose output and improves peripheral insulin sensitivity
• Extended-release formulation minimises GI side effects

Dose management:

• GH dose reduction is the most direct way to lower insulin resistance
• Splitting the daily dose may reduce peak FFA release and subsequent insulin resistance
• Every-other-day protocols reduce cumulative metabolic load